AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · IEX Real-Time Price · USD
2.280
-0.120 (-5.00%)
At close: Apr 25, 2024, 4:00 PM
2.360
+0.080 (3.51%)
After-hours: Apr 25, 2024, 6:42 PM EDT
AN2 Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for AN2 Therapeutics stock have an average target of 6.50, with a low estimate of 6.00 and a high estimate of 7.00. The average target predicts an increase of 185.09% from the current stock price of 2.28.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for ANTX stock from 4 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 5 | 5 | 2 | 0 | 0 | 1 |
| Hold | 0 | 0 | 0 | 4 | 4 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 2 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Hold → Buy Upgrades $6 | Hold → Buy | Upgrades | $6 | +163.16% | Apr 2, 2024 |
| Oppenheimer | Oppenheimer | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Apr 1, 2024 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $23 → $7 | Buy → Hold | Downgrades | $23 → $7 | +207.02% | Feb 13, 2024 |
| Evercore ISI Group | Evercore ISI Group | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Feb 12, 2024 |
| Oppenheimer | Oppenheimer | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Feb 12, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.62
from -2.74
EPS Next Year
-2.50
from -2.62
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | n/a | n/a | 76.3M | 294.4M |
| Avg | n/a | n/a | 37.8M | 253.7M |
| Low | n/a | n/a | n/a | 212.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | 679.4% |
| Avg | - | - | - | 571.5% |
| Low | - | - | - | 463.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -2.30 | -1.92 | -0.56 | 5.85 |
| Avg | -2.62 | -2.50 | -0.88 | 4.01 |
| Low | -2.99 | -2.79 | -1.39 | 2.24 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | - |
| Avg | - | - | - | - |
| Low | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.